Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by jimsenioron Feb 14, 2023 3:43pm
175 Views
Post# 35285968

RE:RE:RE:The Business of Biotech interview...

RE:RE:RE:The Business of Biotech interview...@fox. Yes. I should have read your first post more carefully. It is useful for us longholders to know the mindset of ONC and MC, so as to gauge timing. I am not satisfied that MC is ready to let go; he says partner on Phase 3 and play an active roll, and then advocates buyout at the end. If he really plans to partner, the ATM will likely be running.  And that would be dilution for shareholders. You cannot partner and have a buyout at the same time, but I will stand corrected on that.
As always nothing is really clear, and we are kept guessing. My guess if we get a deal is a buyout because that makes the most sense. But he has to mention partnering and playing a roll. I do agree that he did state buyout. But when? I suppose it could be a negotiation tactic. Who knows.

<< Previous
Bullboard Posts
Next >>